Journal issues > Issue 5, September 2024 > Highlights in melanoma

Highlights in melanoma

SUMMARY

At ASCO 2024, the first results from the phase III NADINA study were presented. Furthermore, the final analysis of the COMBI-AD study demonstrated that one year of adjuvant dabrafenib/trametinib maintains longterm survival benefit in AJCC stage III melanoma. Finally, ASCO featured some interesting presentations on novel strategies to treat melanoma, including the personalised neoantigen vaccine mRNA-4157, the tumour infiltration lymphocyte cell therapy OBX-115, the enhanced oncolytic virus RP2 and neoadjuvant daromun.

(Belg J Med Oncol 2024;18(5):216–20)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top